Literature DB >> 3427330

Surgical approach to inferior vena caval extension of renal carcinoma.

M K O'Donohoe1, F Flanagan, J M Fitzpatrick, J M Smith.   

Abstract

Between 1979 and 1985, 10 patients were treated for renal carcinoma with extension into the inferior vena cava but without evidence of disseminated disease. Two of these had tumour thrombus extension up to the level of the hepatic veins and in four the extension was above the level of the diaphragm, two of which entered the atrium. Thrombus was removed en bloc at radical nephrectomy. Six patients are still alive, with a mean survival of 22 months. There was no correlation between the level of tumour thrombus and perinephric extension or indeed any correlation between tumour thrombus level and overall survival. It is suggested that tumour thrombus in the inferior vena cava, in the absence of metastatic disease, should be managed by radical surgery.

Entities:  

Mesh:

Year:  1987        PMID: 3427330     DOI: 10.1111/j.1464-410x.1987.tb05027.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  4 in total

1.  Small Renal Mass with Level 4 IVC Thrombus.

Authors:  Abhishek Laddha; Priyank Bijalwan; Appu Thomas; Ginil Kumar P
Journal:  Indian J Surg Oncol       Date:  2018-11-28

2.  Radical nephrectomy through total median laparotomy.

Authors:  L Pajor; D Frang; V Szabó; D Répássy
Journal:  Int Urol Nephrol       Date:  1989       Impact factor: 2.370

3.  Vena caval involvement by renal cell carcinoma. Surgical resection provides meaningful long-term survival.

Authors:  D G Skinner; T R Pritchett; G Lieskovsky; S D Boyd; Q R Stiles
Journal:  Ann Surg       Date:  1989-09       Impact factor: 12.969

4.  Prognostic benefit of surgical management in renal cell carcinoma patients with thrombus extending to the renal vein and inferior vena cava: 17-year experience at a single center.

Authors:  Shingo Hatakeyama; Takahiro Yoneyama; Itsuto Hamano; Hiromi Murasawa; Takuma Narita; Masaaki Oikawa; Kazuhisa Hagiwara; Daisuke Noro; Toshikazu Tanaka; Yoshimi Tanaka; Yasuhiro Hashimoto; Takuya Koie; Chikara Ohyama
Journal:  BMC Urol       Date:  2013-10-14       Impact factor: 2.264

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.